Locoregional Therapy plus First-Line Systemic Therapy in Unresectable Locally Advanced Intrahepatic Cholangiocarcinoma
Year: 2026
Type: preprint
Study design: Observational Study
Abstract: Background and purpose Whether locoregional consolidation therapy (LCT) adds benefit to first-line systemic therapy in unresectable, locally advanced intrahepatic cholangiocarcinoma (ICC) is unknown. Methods In this single-centre retrospective cohort (2017–2025), 156 patients receiving gemcitabine-based chemotherapy plus a PD-1/PD-L1 inhibitor, with or without a tyrosine kinase inhibitor, were grouped by concomitant LCT (n = 61; radiotherapy 34, non-radiotherapy 27) or systemic therapy alone (n = 95). Stabilised inverse probability of treatment weighting (sIPTW) balanced 13 covariates; weighted Cox models and sensitivity analyses were used. Results At a median follow-up of 37.0 months, after stabilised inverse probability of treatment weighting, LCT was associated with longer progression-free survival (PFS; 17.35 vs 8.67 months; hazard ratio 0.43, 95% confidence interval 0.29–0.62; P < 0.001) and overall survival (OS; 28.91 vs 20.60 months; HR 0.59, 95% CI 0.39–0.91; P = 0.017). Across analytic approaches, hazard ratios were 0.41–0.55 for PFS and 0.49–0.71 for OS. E-values were 3.00 (PFS) and 2.23 (OS). Growth of existing intrahepatic lesions as the first progression was less frequent after radiotherapy-based consolidation (11.8% vs 41.1%; P = 0.002) but not after non-radiotherapy LCT (48.1% vs 41.1%; P = 0.52). Grade ≥ 3 lymphopenia (63.9% vs 33.7%), any-grade thrombocytopenia (82.0% vs 62.1%) and any-grade gastrointestinal ulceration (14.8% vs 2.1%) were more frequent with LCT, the ulcer excess being confined to radiotherapy-based consolidation (20.6% vs 2.1%; P = 0.001). Conclusion In unresectable ICC treated with first-line systemic therapy, consolidative LCT, and radiotherapy-based consolidation in particular, was associated with longer PFS and OS and fewer intrahepatic failures. Randomised confirmation is required.
Source: Research Square
Institution: Zhongshan Hospital
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Keywords: intrahepatic cholangiocarcinoma, locally advanced unresectable cancer, radiotherapy, gemcitabine, PD-1/PD-L1 inhibitors, tyrosine kinase inhibitors, first-line systemic therapy, progression-free survival, overall survival, gastrointestinal ulceration, lymphopenia, thrombocytopenia, inverse probability of treatment weighting, causal inference
Open Access status: green
Awards: G5520128856, G6832943629, G7764366873
OpenAlex ID: W7225900272
